Litigation Details for Ravgen, Inc. v. Laboratory Corporation of America Holdings (W.D. Tex. 2020)
✉ Email this page to a colleague
Ravgen, Inc. v. Laboratory Corporation of America Holdings (W.D. Tex. 2020)
| Docket | ⤷ Try a Trial | Date Filed | 2020-10-16 |
| Court | District Court, W.D. Texas | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Alan D Albright |
| Jury Demand | Plaintiff | Referred To | |
| Patents | 7,727,720; 9,022,022 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Ravgen, Inc. v. Laboratory Corporation of America Holdings
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Biologic Drugs cited in Ravgen, Inc. v. Laboratory Corporation of America Holdings
The biologic drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for Ravgen, Inc. v. Laboratory Corporation of America Holdings (W.D. Tex. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2020-10-16 | 1 | Complaint | United States Patent Nos. 7,727,720 (the “’720 Patent”) and 7,332,277 (the “’277 Patent”) (collectively…your issued patents – 7,332,277, 7,442,506 and 7,727,720.” (Id. (emphasis added).) U.S. Patent Nos. 7,332,277…Dhallan) (“Our oncology patent that we talked about is US Patent No. 7,727,720.”).) In an email dated …7,332,277 and 7,727,720 are the Patents-in- Suit. 96. In 2015, Sequenom and Ravgen continued…into the claims and descriptions of the US Patent No. 7,727,720.” (Id. at 1.) 97. Additionally | External link to document |
| 2022-07-07 | 129 | Notice of Filing - Redacted Public Version | Claims of U.S. Patent Nos. 7,332,277 (“the ’277 Patent”) and 7,727,720 (“the ’720 Patent”) (collectively…The Asserted Patents Ravgen asserts claims 67, 91, 130 and 132 of the ʼ277 Patent and claim 6 … 2 Ex. A, ’277 Patent at 473:1-5.2 Claim 91 of the ʼ277 Patent ultimately depends on…claims of either the ʼ277 or ʼ720 Patent. In the ʼ277 Patent, the term “cell lysis inhibitor” …is. Ex. B, ʼ720 Patent at 535: 15-21. Accordingly, the claims of the Asserted Patents fail to inform, | External link to document |
| 2022-07-27 | 163 | Response in Opposition to Motion | United States patents, including U.S. Patent Nos. 7,332,277 (“the ’277 patent”) and 7,727,720 (“the ’720…720 patent”) (the “Patents-in- Suit”). Dkt. 1 ¶¶ 1, 16–40. Ravgen’s inventions claimed in the Patents-in-Suit…petitions against the ’277 patent and three IPR petitions against the ’720 patent. Notably, in its decision…instituted two IPR petitions against the ’277 patent and ’720 patent but, again, clarified that it would not…Ravgen’s patented technologies. Second, this Court has recognized that “‘[a] patent holder has | External link to document |
| 2022-08-05 | 179 | Pretrial Disclosures | United States Patent Nos. 7,332,277 (the “’277 Patent”) and 7,727,720 (the “’720 Patent”) (collectively… This is a civil action for patent infringement arising under the patent laws of the United States, …Asserted Patents”). See Dkt. 1. Dr. Ravinder S. Dhallan is the named inventor of the Asserted Patents, which…67, 91, 130, and 132 of the ’277 Patent and claim 6 of the ’720 Patent; (2) the informaSeq Test infringe…claims 91, 130, and 132 of the ’277 Patent and claim 6 of the ’720 Patent; and (3) the Resolution ctDx Lung | External link to document |
| 2022-08-16 | 185 | Order on Motion to Extend Scheduling Order Deadlines | infringes U.S. Patent Nos. 7,332,277 (“the ’277 Patent”) and 7,727,720 (“the ’720 Patent”). Specifically…67, 91, 130, and 132 of the ’277 Patent and claim 6 of the ’720 Patent (collectively, the “Asserted Claims…petitioning the Patent Trial and Appeal Board (the “PTAB”) for IPRs of the Asserted Patents. The PTAB has…instituted since that order. Both the ’277 Patent and ’720 Patent expire on March 13, 2023. In light of the…Fed. Cir. 1991). Third, the ’277 Patent and ’720 Patent expire on March 13, 2023, only three months | External link to document |
| 2022-10-04 | 230 | Sealed Order | United States Patent Nos. 7,727,720 (the “’720 Patent”) and 7,332,277 (the “’277 Patent”) (collectively…Asserted Patents; (2) the validity of ’277 Patent claim 67; and (3) obviousness of ’277 Patent claims …collectively the “Patents-in- Suit”). ECF No. 1 ¶ 1. The Patents-in-Suit “are directed to unconventional, non-routine…Dumont regarding the validity of the Asserted Patents. ECF. No. 120 at 2. Ravgen filed this Motion to…Regarding the Priority Date of the Asserted Patents. An expert’s opinions should be excluded | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
